Roberto Mignone's hedge fund firm Bridger Capital has filed a 13G with the SEC regarding shares of TG Therapeutics (TGTX). Per the filing, Bridger has disclosed a 7.1% ownership stake in TGTX with over 2.39 million shares.
This marks an increase of 894,132 shares since the end of the third quarter. The filing was required due to activity on January 21st.
Per Yahoo Finance, TG Therapeutics is "a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs.."
Tuesday, February 4, 2014
Bridger Capital Boosts TG Therapeutics Stake
blog comments powered by Disqus
